CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology | CGON Stock NewsStockTitan·2 days ago, 09:45 AMCGON0.00%
From Unbundling to Scarcity: The Limits of Aggregation in the Market's PeripheryGlobal Report·Jul 25 at 04:14 AMETSY-2.33%PLG+2.80%
CG Oncology director Leonard Post disposes of 1,000 shares for $71,170PUBT·Jul 17 at 03:15 PMCGON0.00%
How CG Oncology’s Phase II Bladder Cancer Data and 2026 BLA Timeline Will Impact CGON InvestorsSimplywall·Jul 14 at 08:13 PMCGON0.00%
CG Oncology director James Mulay disposes of common shares worth $1.82 millionPUBT·Jul 14 at 03:15 PMCGON0.00%
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Moderate Buy" from AnalystsMarket Beat·Jul 3 at 01:14 AMCGON0.00%UBS+1.93%
CGON: Cretostimogene delivers leading efficacy and safety in NMIBC, targeting a large market opportunityQuartr·Jul 1 at 02:44 AMCGON0.00%
CG Oncology posts investor deck highlighting cretostimogene data in non-muscle invasive bladder cancer trialsPUBT·Jun 30 at 08:56 PMCGON0.00%
